博文
2017年FDA批准新药名单
|||
2017年FDA批准新药名单
诸平
据FDA官网（http://www.fda.org）2017年5月12日提供的最新公布结果，截止2017年5月5日，FDA已经批准了20种新药，约占2016年FDA批准新药数量（22种）的90%。2011-2017年5月5日FDA批准新药数量变化见图1所示。
图1 FDA2011-2017年批准新药数量变化
2017年以来（截止2017年5月5日）FDA批准新药名单见表1。
表1 2017年FDA批准新药一览表
| No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date |
|---|---|---|---|---|
| 20. | Radicava | edaravone | 5/5/20017 | To treat patients with amyotrophic lateral sclerosis (ALS) Press Release |
| 19. | Imfinzi | durvalumab | 5/1/20017 | To treat patients with locally advanced or metastatic urothelial carcinoma Web Post Drug Trials Snapshot |
| 18. | Tymlos | abaloparatide | 4/28/2017 | To treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapies |
| 17. | Rydapt | midostaurin | 4/28/2017 | To treat acute myeloid leukemia Press Release Drug Trials Snapshot |
| 16. | Alunbrig | brigatinib | 4/28/2017 | To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Drug Trials Snapshot |
| 15. | Brineura | cerliponase alfa | 4/27/2017 | To treat a specific form of Batten disease Press Release |
| 14. | Ingrezza | valbenazine | 4/11/2017 | To treat adults with tardive dyskinesia Press Release Drug Trials Snapshot |
| 13. | Austedo | deutetrabenazine | 4/3/2017 | For the treatment of chorea associated with Huntington’s disease Drug Trials Snapshot |
| 12. | Ocrevus | ocrelizumab | 3/28/2017 | To treat patients with relapsing and primary progressive forms of multiple sclerosis Press Release Drug Trials Snapshot |
| 11. | Dupixent | dupilumab | 3/28/2017 | To treat adults with moderate-to-severe eczema (atopic dermatitis) Press Release Drug Trials Snapshot |
| 10. | Zejula | niraparib | 3/27/2017 | For the maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers Press Release Drug Trials Snapshot |
| 9. | Symproic | naldemedine | 3/23/2017 | For the treatment of opioid-induced constipation |
| 8. | Bavencio | avelumab | 3/23/2017 | To treat metastatic Merkel cell carcinoma Press Release Drug Trials Snapshot |
| 7. | Xadago | safinamide | 3/21/2017 | To treat Parkinson’s disease Press Release Drug Trials Snapshot |
| 6. | Kisqali | ribociclib | 3/13/2017 | To treat postmenopausal women with a type of advanced breast cancer Drug Trials Snapshot |
| 5. | Xermelo | telotristat ethyl | 2/28/2017 | To treat carcinoid syndrome diarrhea Press Release Drug Trials Snapshot |
| 4. | Siliq | brodalumab | 2/15/2017 | To treat adults with moderate-to-severe plaque psoriasis Press Release Drug Trials Snapshot |
| 3. | Emflaza | deflazacort | 2/9/2017 | To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD) Press Release Drug Trials Snapshot |
| 2. | Parsabiv | etelcalcetide | 2/8/2017 | To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis Drug Trials Snapshot |
| 1. | Trulance | plecanatide | 1/19/2017 | To treat Chronic Idiopathic Constipation (CIC) in adult patients. Press Release Drug Trials Snapshot |
* This information is currently accurate. In rare instances, it may be necessary for FDA to change a drug’s new molecular entity (NME) designation or the status of its application as a novel new biologics license application (BLA). For instance, new information may become available which could lead to a reconsideration of the original designation or status. If changes must be made to a drug’s designation or the status of an application as a novel BLA, the Agency intends to communicate the nature of, and the reason for, any revisions as appropriate.
更多更新信息请浏览FDA官网。
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
https://blog.sciencenet.cn/blog-212210-1055621.html
上一篇：宝鸡神农镇民间手工艺品照片
下一篇：2017年FDA药品召回一览表
